Is it time to consider neoadjuvant treatment as the standard of care in oesophageal cancer?
暂无分享,去创建一个
[1] Val Gebski,et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. , 2007, The Lancet. Oncology.
[2] M. Ebert,et al. Current treatment approach to locally advanced esophageal cancer: is resection mandatory? , 2006, Future oncology.
[3] J. Ajani,et al. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] C. V. D. van de Velde,et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. , 2006, The New England journal of medicine.
[5] R. Langer,et al. Association of Pretherapeutic Expression of Chemotherapy-Related Genes with Response to Neoadjuvant Chemotherapy in Barrett Carcinoma , 2005, Clinical Cancer Research.
[6] A. Venturi,et al. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis , 2004, Gut.
[7] J. Siewert,et al. Improved Prognosis of Resected Esophageal Cancer , 2004, World Journal of Surgery.
[8] F. Lordick,et al. Neoadjuvant therapy for oesophagogastric cancer , 2004, The British journal of surgery.
[9] Wolfgang A Weber,et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.